{"filing":{"accession_number":"0001493152-26-029666","cik":"0001113423","ticker":"CSCIF","company_name":"COSCIENS Biopharma Inc.","form":"6-K","filing_date":"2026-06-22","report_date":null,"primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1113423/000149315226029666/form6-k.htm"},"events":[{"id":12943,"run_id":11483,"accession_number":"0001493152-26-029666","anchor_item_number":"EX-99.1","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"This announcement discloses implementation details of a Share Capital Amendment (consolidation followed by a split) that was approved by shareholders at the June 17, 2026 annual general and special meeting. The amendment materially affects share structure and shareholder rights—holders of fewer than 150 shares receive cash consideration while others experience a net 3:1 reduction in holdings. Additionally, the company plans to file a Form 15 to suspend U.S. reporting obligations, which is a material governance and regulatory change. While the shareholder vote itself occurred, this exhibit announces the effective date and operational mechanics, making it a governance event with material consequences for investors.","company_name":"COSCIENS Biopharma Inc.","ticker":"CSCIF","filing_date":"2026-06-22","form":"6-K","submitted_at":null,"items":[{"id":9937,"accession_number":"0001493152-26-029666","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses implementation details of a Share Capital Amendment (consolidation followed by a split) that was approved by shareholders at the June 17, 2026 annual general and special meeting. The amendment materially affects share structure and shareholder rights—holders of fewer than 150 shares receive cash consideration while others experience a net 3:1 reduction in holdings. Additionally, the company plans to file a Form 15 to suspend U.S. reporting obligations, which is a material governance and regulatory change. While the shareholder vote itself occurred, this exhibit announces the effective date and operational mechanics, making it a governance event with material consequences for investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-23T10:06:22.349819+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9937,"accession_number":"0001493152-26-029666","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses implementation details of a Share Capital Amendment (consolidation followed by a split) that was approved by shareholders at the June 17, 2026 annual general and special meeting. The amendment materially affects share structure and shareholder rights—holders of fewer than 150 shares receive cash consideration while others experience a net 3:1 reduction in holdings. Additionally, the company plans to file a Form 15 to suspend U.S. reporting obligations, which is a material governance and regulatory change. While the shareholder vote itself occurred, this exhibit announces the effective date and operational mechanics, making it a governance event with material consequences for investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-23T10:06:22.349819+00:00","company_name":"COSCIENS Biopharma Inc.","ticker":"CSCIF","filing_date":"2026-06-22"}]}